Document is current
Any future updates will be listed below
-
Authors
Barata, Fernando
Aguiar, Carlos
Marques, Tiago Reis https://orcid.org/0000-0003-0602-7661
Marques, José Bravo https://orcid.org/0000-0001-9848-5832
Hespanhol, Venceslau https://orcid.org/0000-0001-6577-0063
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Accepted: 18 May 2021
First Online: 3 June 2021
Declarations
:
: This study was funded by Pfizer.
: FB received speaker’s fees and honoraria from AstraZeneca, Boeringher Ingelheim, Bristol Myers Squibb, MSD Oncology, Pfizer, Roche and Takeda for participating in advisory boards. CA has received honoraria from Pfizer for consulting. TRM has conducted research funded by the Medical Research Council (UK), King´s Health Partners and King’s College London, and has received honoraria for speaking and chairing engagements from Lundbeck, Janssen, Astellas and Pfizer. JBM and VH received honoraria from Pfizer for participating in advisory boards.
: Not applicable.
: Not applicable.
: All authors approved the publication of this article.
: Data sharing is not applicable as no new data were created or analysed in this study.
: Not applicable.
: FB devised and coordinated the project. All authors participated in the advisory board in which the recommendations were discussed, and contributed to the writing of the manuscript. All authors also read and approved the final version of this manuscript.
